A novel AKT3 mutation in melanoma tumours and cell lines

[1]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[2]  S. H. Lee,et al.  Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias , 2008, British Journal of Cancer.

[3]  Yiling Lu,et al.  Pharmacodynamic Markers of Perifosine Efficacy , 2007, Clinical Cancer Research.

[4]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[5]  A. Newton,et al.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.

[6]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[7]  D. Pinkel,et al.  MC1R germline variants confer risk for BRAF-mutant melanoma. , 2006, Science.

[8]  D. Pinkel,et al.  PI3-kinase subunits are infrequent somatic targets in melanoma. , 2006, The Journal of investigative dermatology.

[9]  F. Haluska,et al.  Genetic Alterations in Signaling Pathways in Melanoma , 2006, Clinical Cancer Research.

[10]  J. Hansson,et al.  Mutations of PIK3CA are rare in cutaneous melanoma , 2006, Melanoma research.

[11]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[12]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[13]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[14]  W. Shih,et al.  Detection of B-RAF and N-RAS mutations in human melanoma. , 2005, Journal of the American College of Surgeons.

[15]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[16]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[17]  Robert D Cardiff,et al.  Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.

[18]  J. Downward.  PI 3-kinase, Akt and cell survival. , 2004, Seminars in cell & developmental biology.

[19]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[20]  M. Deichmann,et al.  Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma , 2002, Melanoma research.

[21]  M. Deichmann,et al.  Mutations of the activation-associated phosphorylation sites at codons 308 and 473 of protein kinase B are absent in human melanoma , 2001, Archives of Dermatological Research.

[22]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[23]  T. Godfrey,et al.  Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. , 2000, Cancer research.

[24]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[25]  J. Trent,et al.  Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. , 1995, Cancer genetics and cytogenetics.

[26]  I. Fidler,et al.  A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. , 1984, Journal of the National Cancer Institute.

[27]  G. Viglietto,et al.  Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. , 2008, Cell cycle.

[28]  C. Warneke,et al.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.